Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Crescent Biopharma (CBIO) Operating Margin (2016 - 2026)

Crescent Biopharma has reported Operating Margin over the past 8 years, most recently at 2380.08% for Q1 2026.

  • Quarterly Operating Margin changed N/A to 2380.08% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 15701.25% through Mar 2026, up 3540238.0% year-over-year, with the annual reading at 1407.52% for FY2025, N/A changed from the prior year.
  • Operating Margin was 2380.08% for Q1 2026 at Crescent Biopharma, up from 17804.21% in the prior quarter.
  • Over five years, Operating Margin peaked at 2380.08% in Q1 2026 and troughed at 17804.21% in Q2 2022.